LONA
Leonabio Inc
NASDAQ · Pharmaceuticals
$4.58
-0.21 (-4.38%)
Income Statement
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 9.05M | 8.81M | 7.55M |
| Net Income | 1.50M | 1.95M | 1.65M |
| EPS | — | — | — |
| Profit Margin | 16.6% | 22.2% | 21.9% |
| Rev Growth | -8.9% | +8.5% | +16.9% |
Balance Sheet
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Total Debt | 7.86M | 7.59M | 7.46M |
| Total Equity | 24.10M | 23.72M | 25.10M |
| D/E Ratio | 0.33 | 0.32 | 0.30 |
Cash Flow
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| EBITDA | 2.36M | 2.47M | 1.95M |
| Free Cash Flow | 1.28M | 1.29M | 705.7K |